Tetraxetan

Tetraxetan

SCHEMBL1496261

NCC(N)=O.NCC(N)=O.NCC(N)=O.NCC(N)=O.O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.50
KDM4E B2RXH2 2/20 0.45
SLC6A9 P48067 2/20 0.41
GLRA1 P23415 1/20 0.41
OR51E2 Q9H255 1/20 0.41
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
S1PR1 P21453 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
ALDH1A1 P00352 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL308073 0.90 HSD17B10 (0.54) HSD17B10KDM4ESLC6A9GLRA1OR51E2
Tetraxetan SCHEMBL3364489 0.90 HSD17B10 (0.54) HSD17B10KDM4ESLC6A9GLRA1OR51E2
SCHEMBL8036117 0.88 KDM4E (0.58) HSD17B10KDM4ESLC6A9POLBPKM
SCHEMBL16731723 0.88 KDM4E (0.58) HSD17B10KDM4ESLC6A9POLBPKM
SCHEMBL15043622 0.88 KDM4E (0.58) HSD17B10KDM4ESLC6A9POLBPKM
SCHEMBL26105210 0.88 KDM4E (0.58) HSD17B10KDM4ESLC6A9POLBPKM
Tetraxetan SCHEMBL21248095 0.87 HSD17B10 (0.56) HSD17B10KDM4ESLC6A9POLBPKM
SCHEMBL10562348 0.86 KDM4E (0.56) HSD17B10KDM4ESLC6A9POLBPKM
SCHEMBL6848102 0.84 HSD17B10 (0.64) HSD17B10KDM4ESLC6A9TSHRS1PR1
SCHEMBL173508 0.84 HSD17B10 (0.64) HSD17B10KDM4ESLC6A9TSHRS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1331012-A1 Responsive paramagnetic MRI contrast agents BRACCO IMAGING S.p.A. (IT) 2003-07-30 EP claimed
US-8318134-B2 Responsive paramagnetic MRI contrast agents BRACCO IMAGING S.P.A. (IT) 2012-11-27 US disclosed
EP-1469890-B1 RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS BRACCO IMAGING SPA (IT) 2011-08-10 EP disclosed
EP-2298362-A1 Responsive paramagnetic MRI contrast agents Bracco Imaging S.p.A (IT) 2011-03-23 EP disclosed
US-20090234221-A1 RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS BRACCO IMAGING S.P.A. (IT) 2009-09-17 US disclosed
US-7524483-B2 Responsive paramagnetic MRI contrast agents BRACCO IMAGING S.P.A. (IT) 2009-04-28 US disclosed
US-20050191243-A1 Responsive paramagnetic mri contrast agents BRACCO IMAGING S.P.A. (IT) 2005-09-01 US disclosed
EP-1469890-A1 RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS Bracco Imaging S.p.A. (IT) 2004-10-27 EP disclosed
WO-2003063912-A1 RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS BRACCO IMAGING S.P.A. (IT) 2003-08-07 WO disclosed
EP-1331012-A1 Responsive paramagnetic MRI contrast agents BRACCO IMAGING S.p.A. (IT) 2003-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234221-A1 RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS MYT1, PRTN3, CECR2 HSD17B10 4757/4885KDM4E 3172/4885SLC6A9 343/4885
US-20050191243-A1 Responsive paramagnetic mri contrast agents MYT1, PRTN3, CECR2 HSD17B10 4757/4885KDM4E 3172/4885SLC6A9 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.